169 related articles for article (PubMed ID: 26732944)
1. Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting.
Ng T; Mazzarello S; Wang Z; Hutton B; Dranitsaris G; Vandermeer L; Smith S; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(2):337-44. PubMed ID: 26732944
[TBL] [Abstract][Full Text] [Related]
2. Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience.
Hernandez Torres C; Mazzarello S; Ng T; Dranitsaris G; Hutton B; Smith S; Munro A; Jacobs C; Clemons M
Support Care Cancer; 2015 Nov; 23(11):3341-59. PubMed ID: 26108169
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
Chan A; Low XH; Yap KY
J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
[TBL] [Abstract][Full Text] [Related]
4. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
5. Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Clemons M; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Segal R; Dent S; Gertler S; Song X; Wheatley-Price P; Dranitsaris G
JAMA Oncol; 2016 Feb; 2(2):225-31. PubMed ID: 26562292
[TBL] [Abstract][Full Text] [Related]
6. Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
Anticancer Res; 2018 Feb; 38(2):877-884. PubMed ID: 29374715
[TBL] [Abstract][Full Text] [Related]
7. Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.
De Laurentiis M; Bonfadini C; Lorusso V; Cilenti G; Di Rella F; Altavilla G; Otero M; Ardizzoia A; Marchetti P; Peverelli G; Amoroso D; Vecchio S; Fiorio E; Orecchia S
Support Care Cancer; 2018 Dec; 26(12):4021-4029. PubMed ID: 29943152
[TBL] [Abstract][Full Text] [Related]
8. Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer--an inspection of the evidence base informing clinical decision-making.
Hutton B; Clemons M; Mazzarello S; Kuchuk I; Skidmore B; Ng T
Cancer Treat Rev; 2015 Dec; 41(10):951-9. PubMed ID: 26442474
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.
Clemons M; Dranitsaris G; Sienkiewicz M; Sehdev S; Ng T; Robinson A; Mates M; Hsu T; McGee S; Freedman O; Kumar V; Fergusson D; Hutton B; Vandermeer L; Hilton J
Breast; 2020 Dec; 54():278-285. PubMed ID: 33242754
[TBL] [Abstract][Full Text] [Related]
10. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.
Llombart-Cussac A; Ramos M; Dalmau E; García-Saenz JA; González-Farré X; Murillo L; Calvo L; Morales S; Carañana V; González A; Fernández-Morales LA; Moreno F; Casas MI; Angulo Mdel M; Cámara MC; Garcia-Mace AI; Carrasco E; Jara-Sánchez C
Eur J Cancer; 2016 May; 58():122-9. PubMed ID: 26994459
[TBL] [Abstract][Full Text] [Related]
11. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced nausea and vomiting in Asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy.
Bourdeanu L; Frankel P; Yu W; Hendrix G; Pal S; Badr L; Somlo G; Luu T
J Support Oncol; 2012; 10(4):149-54. PubMed ID: 22222249
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of nausea and vomiting during FEC regimen for breast cancer after the novel antiemetic agent - introduction using MASCC antiemesis tool].
Oshiro C; Kamigaki S; Nakamura Y; Arai T; Kanai Y; Fujino M; Fujii C; Hamaguchi Y; Iseki C; Hachino Y; Furukawa H
Gan To Kagaku Ryoho; 2012 Feb; 39(2):241-4. PubMed ID: 22333635
[TBL] [Abstract][Full Text] [Related]
17. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study.
Booth CM; Clemons M; Dranitsaris G; Joy A; Young S; Callaghan W; Trudeau M; Petrella T
J Support Oncol; 2007 Sep; 5(8):374-80. PubMed ID: 17944146
[TBL] [Abstract][Full Text] [Related]
19. Late chronotypes are associated with neoadjuvant chemotherapy-induced nausea and vomiting in women with breast cancer.
Lee KM; Jung DY; Hwang H; Kim WH; Lee JY; Kim TY; Im SA; Lee KH; Spiegel D; Hahm BJ
Chronobiol Int; 2017; 34(4):480-491. PubMed ID: 28362229
[TBL] [Abstract][Full Text] [Related]
20. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
